A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease
Status:
Completed
Trial end date:
1993-05-01
Target enrollment:
Participant gender:
Summary
To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who
are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to
monitor adverse effects of AZT.
Previous studies with pediatric patients have shown improvements in clinical, immunologic,
and virologic parameters with administration of AZT.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)